Case Western Reserve University School of Medicine

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

Retrieved on: 
Wednesday, October 4, 2023
Health, Genetics, Radiology, Clinical Trials, Oncology, Docetaxel, NRG, Prostate-specific antigen, Radiation, University, DM, ASTRO, MFS, Clinical trial, University Hospitals Cleveland Medical Center, ADT, Research, Risk, Prostate, Gene expression, Radiation therapy, Maryland School, University of Maryland School of Medicine, Patient, Physician, Annual general meeting, Case Western Reserve University School of Medicine, Urology, Society, PSA, American Society for Radiation Oncology, Biopsy, Prostate cancer, Medical imaging

(Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer.
  • Data from a second study presented at ASTRO 2023 reveal there is minimal to moderate risk-score correlation between the gene expression signatures of three commercially available genomic classifiers, including the Decipher Prostate test.
  • Researchers generated Decipher Prostate test scores using biopsy samples from 183 patients, who were followed for a median of 9.9 years.
  • Additionally, patients with higher-risk Decipher Prostate genomic scores had worse DM (sHR 2.82, 95% CI) compared to those with lower-risk scores.

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Retrieved on: 
Friday, August 18, 2023
Injection, Regeneron Pharmaceuticals, Bayer, Cataract, Thomas Jefferson University, Case Western Reserve University School of Medicine, Diabetic retinopathy, Retina, Intraocular pressure, Floater, Patient, Retinal, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, DME, Ophthalmology

TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) every 4 weeks (monthly) for the first 3 months across all indications, followed by 8 mg every 8 to 16 weeks (2 to 4 months) in wAMD and DME and every 8 to 12 weeks (2 to 3 months) for DR.

Key Points: 
  • TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).
  • “More than 10 years ago, we fundamentally changed the way that certain serious retinal diseases were treated with the introduction of EYLEA.
  • EYLEA 4U helps patients understand how EYLEA HD may be covered by their health insurance plans and assists eligible patients who need financial assistance for their EYLEA HD prescription.
  • In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Friday, August 18, 2023
Co-leaders of the Scottish Green Party, Cleveland Clinic, Code, Case Comprehensive Cancer Center, Clinical trial, SNO, Molecular medicine, Tokyo Stock Exchange, Case Western Reserve University School of Medicine, Poster, Standard Market Design, Pharmaceutical industry, Tobacco, Glioblastoma

LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.

Key Points: 
  • LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.
  • The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.
  • The presentation details are as follows:

SightMD Welcomes Robert Spector, MD to its expert team in New York

Retrieved on: 
Monday, August 14, 2023
Learning, Music, University, American Board of Ophthalmology, Teaching, American Academy, University of Iowa, American Academy of Ophthalmology, Golf, American Academy of Pediatrics, Bascom Palmer Eye Institute, Public key certificate, American Board of Commissioners for Foreign Missions, MD, Patient, Case Western Reserve University School of Medicine, Cataract, Neuro-ophthalmology, Family, Society, Nursing, Pediatric ophthalmology, Ophthalmology, Growth, Medicine

HAUPPAUGE, N.Y., Aug. 14, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Robert Spector, MD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Robert Spector, MD to its expert team.
  • HAUPPAUGE, N.Y., Aug. 14, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Robert Spector, MD to its expert team.
  • Dr. Robert T. Spector, M.D., F.A.C.S.
  • SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team.

The Joint Commission announces new chief innovation officer

Retrieved on: 
Monday, July 17, 2023
Joint Commission, Accreditation, University Hospitals Cleveland Medical Center, MSHA, Doctor of Philosophy, MACP, Colorectal surgery, Certification, Agency for Healthcare Research and Quality, Baldwin Wallace University, MD, Patient safety, Press Ganey Associates, Knowledge, General surgery, Case Western Reserve University School of Medicine, Joint, AHRQ, Health, Safety, Management, Medical device, Nursing, Cleveland Clinic

Dr. Merlino brings a wealth of knowledge and expertise to spearhead The Joint Commission's vision for evidence-based, data-driven, and outcomes-oriented health care.

Key Points: 
  • Dr. Merlino brings a wealth of knowledge and expertise to spearhead The Joint Commission's vision for evidence-based, data-driven, and outcomes-oriented health care.
  • As chief innovation officer, Dr. Merlino will provide day-to-day focus on the transformation of The Joint Commission’s services; utilizing data and innovation to inform strategic initiatives which advance health care quality and safety worldwide.
  • Dr. Merlino currently serves as chief clinical transformation officer at Cleveland Clinic, overseeing enterprise strategy, business development, safety, quality, and patient experience.
  • "Jim’s appointment marks a significant milestone for our organization, as we welcome a visionary and effective leader in patient-centered innovation in quality and safety,” says Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, president and chief executive officer, The Joint Commission Enterprise.

Medical Technology: The Innovation Imperative for Growth Stage Companies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, June 28, 2023
Partnership, Weatherhead School of Management, ISO, Health technology, Innovation, Thought, Creativity, Ministry of Science, Innovation, Technology and Telecommunications, Case Western Reserve University School of Medicine, Demand generation, FDA, Medtech, Medical device, Risk management, Management, Engineering

TORONTO, June 28, 2023 /PRNewswire-PRWeb/ -- An exciting, free webinar in the medical device industry is set to happen, with insights into innovation strategies for growth-stage companies to be shared by some of the industry's most experienced professionals. This webinar will provide an opportunity for attendees to hear from founders, CEOs and executives about the importance of innovation for growth-stage companies and gain valuable insights into strategies for bringing differentiated medical devices to market.

Key Points: 
  • In this free webinar, learn how leading medical device companies and leaders are thinking about strategies used to bring differentiated medical devices to market.
  • Attendees will understand how innovation and creativity can be the biggest competitive differentiator in a high-regulated industry.
  • The featured speakers will discuss how to apply best practices in medical device product development and commercialization.
  • The webinar, titled "Medical Technology: The Innovation Imperative for Growth Stage Companies," is being moderated by Brandon Bogdalek, Vice President of Demand Generation at Veranex , a healthcare product innovation and commercialization partner known for its human-centered design and deep engineering capability.

ADEA Announces 2023-24 Fellows of Its Inaugural Council of Deans Fellowship

Retrieved on: 
Wednesday, June 21, 2023
Health, Other Education, University, Dental, Education, Archives of Oral Biology, Experimental pathology, DRS, CWRU, Maryland School, Chemistry, Fellows, Research, Postgraduate education, CODA, Al-Ghad International Health Sciences Colleges, Prosthodontics, Exhibition, M.A, Indiana University School of Dentistry, Harvard School of Dental Medicine, Dean (education), Oral medicine, Pathology, Case Western Reserve University School of Medicine, Oral and maxillofacial pathology, Sacroiliac joint, University of Siena, ADEA, Western University, American Academy, Association of Christian Universities and Colleges in Asia, Otorhinolaryngology, Diplom, University of Maryland School of Dentistry, Dentistry, New York University, Orofacial pain, Medicine

ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.

Key Points: 
  • ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.
  • The ADEA CDF is a year-long, part-time fellowship aimed at creating a diverse pipeline of future leaders who will assume roles as dental school deans and other senior university leadership positions.
  • The ADEA CDF will increase the number of qualified candidates for deanships and equip them with the skills and experiences to help them succeed.
  • The ADEA CDF Program Director is Dean Emeritus Steven Friedrichsen, D.D.S., of Western University of Health Sciences College of Dental Medicine.

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chief scientific officer, Collateral circulation, DMAC, University, Senior, Internal medicine, Patient-Centered Outcomes Research Institute, Harvard T.H. Chan School of Public Health, Stroke, TPA, Harvard University, Associate, Bangladesh Technical Education Board, Harvard Medical School, NYSE, Master of Science, Public health, Miami University, Publication, National academy, Beth Israel Hospital, Patient, Division, Neuromodulation, PCORI, Executive Committee, Case Western Reserve University School of Medicine, S-1 Executive Committee, Biostatistics, HEAL, Neurology, NIH, Interventional cardiology, Pharmaceutical industry, Nursing, Science, Medtronic, Brigham, Parkland Memorial Hospital, Medicine

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
  • Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee.
  • Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009.
  • Before joining Medtronic, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston.

Mymee's Personalized Trial & Care Platform Helps Autoimmune Disease Patients Reverse Flares, New Research Shows

Retrieved on: 
Tuesday, May 16, 2023
Trigger, Long COVID, Factorization of polynomials, Flare, DMARD, Elijah Cummings Lower Drug Costs Now Act, Rx, Arthralgia, Anxiety, Case Western Reserve University School of Medicine, RMD, Quality of life, Research, COVID, Pain, DMTS, DSM-IV codes, Medical director, Patient, Risk, Autoimmune disease, OTC, Joint, HIPAA, Autoimmunity, Fatigue, Pharmaceutical industry, Nursing, Medical device, Medical imaging, Birth control, Rheumatology, Quality of life (healthcare), Medicine

NEW YORK, May 16, 2023 /PRNewswire/ -- Today Mymee Inc, the pioneer in personalized trial & care for autoimmune disease & long COVID patients, announced the publication of new peer-reviewed research in RMD Open. The study found that autoimmune disease and Long COVID patients with moderate to severe symptoms achieved statistically significant, clinically meaningful improvements in all10 PROMIS® Health-Related Quality of Life (HRQoL) domains.

Key Points: 
  • The bigger challenge is that >65% of rheumatic patients have inadequate response to autoimmune drugs in the real world.
  • The personalized trial process helps patients directly correlate symptoms to triggers, add back activities, manage sensitivities and adjust drugs with their physician, if necessary.
  • Key characteristics and findings from Mymee's personalized trial research included:
    Reversing flares: >85% of patients with moderate to severe symptoms saw improvements in HRQoL.
  • For more information on Mymee's research and personalized trial & care platform to help autoimmune Rx non-responders reverse uncontrolled flares, please visit www.mymee.com

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

Retrieved on: 
Tuesday, May 2, 2023
Oncology, Health, Consumer, Genetics, Clinical Trials, Men, Biotechnology, NRG, Radiation, Prostate cancer, Gleason, Survival, University Hospitals Cleveland Medical Center, National Cancer Institute, ADT, Prognosis, National Comprehensive Cancer Network, Radiation therapy, NCCN, Journal of the National Comprehensive Cancer Network, HIV disease progression rates, Patient, Canadian International Council, Physician, Risk, SHR, Case Western Reserve University School of Medicine, Urology, RT, Biology, Metastasis, Biopsy, Medical imaging, Physics

(Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) validate the clinical utility of the company’s Decipher Prostate Genomic Classifier for helping to guide treatment selection in men with intermediate-risk prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) validate the clinical utility of the company’s Decipher Prostate Genomic Classifier for helping to guide treatment selection in men with intermediate-risk prostate cancer.
  • The findings are from NRG Oncology/RTOG 0126, a Phase 3 randomized clinical trial of patients with intermediate-risk prostate cancer treated with definitive radiotherapy without concomitant hormone therapy.
  • This is the first randomized study to validate any gene-expression biomarker in this patient population, adding further evidence to support the Decipher Prostate test’s utility.
  • Overall, men in the study with higher Decipher Prostate test scores had worse 10-year outcomes with radiotherapy (RT) alone compared to men with lower Decipher Prostate test scores.